`
Sunday, 25 June 2017

Drug Discovery News

  • Boehringer, Lilly complete type 2 diabetes study

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 12 Nov, 2012

    Singapore: Recruitment of patients for CAROLINA (cardiovascular outcome study of Linagliptin versus Glimepiride in patients with type 2 diabetes) by Boehringer Ingelheim and Eli Lilly has b...Read more

  • Linagliptin efficacy further established in specific patient populations

    Drug Discovery |  News | By Nandita Singh | 0 Comment | 12 Nov, 2013

    Seoul: Boehringer Ingelheim and Eli Lilly & Company have announced new data that reinforces the efficacy and tolerability of linagliptin in patients with Type 2 Diabetes (T2D) and liver...Read more

  • CSL Behring seeks Japan PMDA approval for Hemophilia drug

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 22 Dec, 2015

    Global biotherapeutics company CSL Behring has submitted its new drug application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its investigational fusion protein l...Read more

  • Boehringer Ingelheim, Hanmi to co-develop lung cancer drug

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 30 Jul, 2015

    Singapore: Boehringer Ingelheim and Korea's Hanmi Pharmaceutical have collaborated for the development and global commercialisation rights, except South Korea, China and Hong Kong, of HM617...Read more

  • Charleston Laboratories, Daiichi Sankyo receives FDA acceptance for CL-108 NDA

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 14 Jun, 2016

    Singapore: New Jersey's Charleston Laboratories Inc and Japanese major Daiichi Sankyo Inc have announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug ...Read more

  • German firm proceeds on ebola vaccine trial

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 04 Jun, 2015

    Singapore: Germany based complex biologics development and manufacturing specialist, ProBioGen, has proceeded on the clinical trial of its investigational vaccine against Ebola virus diseas...Read more

  • Australian researchers find key gene behind Type 2 Diabetes

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 23 May, 2016

    A finding, published in the Latin American Herald Tribune, says that a genetic study of people with Down's syndrome helped identify a key gene linked to type 2 diabetes. The outcome of the ...Read more

  • Multiple myeloma treatment market to reach $8.9 bn by 2021, analyst

    Drug Discovery |  Analysis | By BioSpectrum Bureau | 0 Comment | 21 Aug, 2015

    Singapore: Global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate compound annual growth rate (CAGR) of 4.6 pe...Read more

  • Novartis buys GSK's antibody drug, Ofatumumab

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 21 Aug, 2015

    Singapore: Novartis has proceeded to acquire all remaining rights of GSK's  Ofatumumab, a fully human monoclonal antibody which targets CD20, being developed for relapsing remitting multip...Read more

  • Bionomics files patent application for cancer drug

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 16 Jun, 2015

    Singapore: Bionomics, a biopharmaceutical company, has filed a patent application for BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer. The new patent is...Read more

  • Teijin, Pulmagen enter agreement for asthma drug

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 28 Sep, 2012

    Singapore: Tokyo-based Teijin Pharma, the core company of the Teijin Group's healthcare business, and Pulmagen Therapeutics, a UK-based drug development company, have signed an exclusive l...Read more

  • FDA approves Novartis' drug for rare blood disorder

    Drug Discovery |  Regulatory | By BioSpectrum Bureau | 0 Comment | 13 Jun, 2015

    Singapore: Novartis has recieved USFDA approval for Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insuf...Read more

  • Agilent, Queensland univ join hands for cancer research

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 21 Nov, 2013

    Singapore: Agilent Technologies plans to collaborate with the University of Queensland Center for Clinical Research in Brisbane, Australia, to increase understanding of the genomic differen...Read more

  • CrystalGenomics partners with Dong-A for Acelex commercialization

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 14 Aug, 2015

    Singapore: Korea based CrystalGenomics has signed a sales and marketing agreement with Dong-A ST for the commercialization of Acelex (polmacoxib) in Korea. Acelex is a tissue-selective, on...Read more

  • Japanese researchers discover potential drug target for muscle disease

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 24 Aug, 2015

    Tokyo: In collaboration with the Institute for Frontier Medical Sciences at Kyoto University, a team of CiRA researchers have designed a model that reprograms fibroblasts to the early stage...Read more

  • AMRI acquires spanish API firm at $174 mn

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 20 Jul, 2015

    Singapore: AMRI has acquired all the outstanding shares of Spanish firm, Gadea Pharmaceutical Group, specializing in technically complex active pharmaceutical ingredients (APIs) and finishe...Read more

  • Kowa, Chugai to market liver cancer drug

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 21 Jul, 2015

    Singapore: Japan's Kowa Company and Chugai Pharmaceutical have entered into license agreement for liver cancer drug peretinoin under which Kowa will acquire the marketing authorization, and...Read more

  • SCIEX expands lipidomics portfolio

    Drug Discovery |  News | By BioSpectrum Bureau | 0 Comment | 17 Jun, 2015

    Singapore: SCIEX, a life science analytical technologies provider, and Metabolon, a global company focused on metabolomics, have entered into a multi-year collaboration to develop and expan...Read more

Survey Box

Will Asia- Pacific healthcare IT market hit the double digit growth in the next five years?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls